Medeon Biodesign, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 04, 2021 at 07:02 pm EDT
Share
Medeon Biodesign, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 9.75 million compared to TWD 8.97 million a year ago. Net loss was TWD 178.81 million compared to TWD 63.79 million a year ago. Basic loss per share from continuing operations was TWD 2.45. Diluted loss per share from continuing operations was TWD 2.45. Basic loss per share was TWD 2.45 compared to TWD 0.88 a year ago. Diluted loss per share was TWD 2.45 compared to TWD 0.88 a year ago.
For the nine months, sales was TWD 59.01 million compared to TWD 40.56 million a year ago. Net income was TWD 2,185.08 million compared to net loss of TWD 179.32 million a year ago. Basic earnings per share was TWD 30.02 compared to basic loss per share of TWD 2.45 a year ago. Diluted earnings per share was TWD 30.02 compared to diluted loss per share of TWD 2.45 a year ago.
Medeon Biodesign, Inc. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of medical equipment. The Company's main products include medical apparatus and instruments used in laparoscopic minimally invasive surgeries and cardiac catheter-related minimally invasive surgeries. The Company distributes its products in domestic market and to overseas markets.
MEDEON BIODESIGN, INC. 
